{"ticker": {"uuid": "21dd8bff-3cf2-477b-be71-544eb5bb229e", "symbol": "CMPSN", "name": "COMPASS PATHWAYS PLC", "exchange": "MEX", "country": "MX", "sector": "Healthcare", "industry": "Medical Care Facilities"}, "articles": [{"title": "Why is Compass Pathways stock being clobbered today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPck03SmxNWGZ6dHh5RGVVcUZKSjA3bFVpdTNsWHlJbFNKR0czdnhIV2UyWm56WTVBdEw1aXc5QWIwWnJBMDVSMkhSOFpGMERhVnJLS3VWQ0FOd1ZBNWpPenVya0ZCQ2F2bUR3QWFJTy1OWjJXSVRtX3hVSHlIbHhyNnFsS1h2T25BeTUzLWt3d3ZHcXRZdEpGdnBUQ2h5NEJ2Z1pNT0VUaTNZa3VLTWVtWHJzbw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways stock rating reaffirmed at Buy by TD Cowen", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPM2VZR2kzNDhxOVRhY2RnbjBSXzlReWx4NG9MSzZNbU1uUHJWd2UxZGFUc1Q2bTgxblRJLWhIYzkzb2JHUHdjNWRZNElBU2ZwOGQydlFwNFVEYkJ5NHpPbWtNS05YUnRHVlZzVVk1d1hQekV2akw2SVYxVVdXbE1JMU90eTVKSHhncU1rYXpYTWFZLXRQd0NVWW5LOGkydHdWODlXUDBJVkwxZ0U4akppN21jUTA5UDNZaHB3?oc=5", "source_name": "Investing.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Compass Pathways stock surging 9% today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQZDFTM09yWXU3QkdLR2dqWXNLc3J0VGhMVVhlNTJDcUZuSXpPdUcwdDJIQWdqNFctTWJPSmx3RFFQTnZMNVh3dS1LS1VXNl8xOXJPQndZUnpON1Mwb205QUROZkoyNjVueHZlMEFSTUY4MEY3d3dWaU1uUzN4b1NicUVXSTZTRGxMLUJrZ1BWai14QjZoQ19TSG9IbVlRWGtTQmtuMlZNU01MUVU?oc=5", "source_name": "Investing.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways stock hits 52-week high at 12.48 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNdGF3dXQ3YVNVYlRWNFBGWTI4TDJFM0FGWWh5OGVBS1o1b1hpTnQ2ckEyaEczbjhlbm5hVU5XWHJjRy1jY0RwbEJ5QXdrNXVtWWwxYnl6cmlUcmxVR2pBdDR3R0htV1VCVG1QSklNazZQLXFVelFqRHU4WHJrTWF1dHpocFF4QURzcm5jUXcyWU9Lamp0RW1fbFVINjNrc212RzRjWVVXd3p1dzNZ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wolfe Research initiates Compass Pathways stock with outperform rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNRGhmTV9WNDRBbEVOdmE0MmM1SDBzNzNlOEl5V01pRDRmaC1oVkdreElSWDhUdm1wSm5pN3JyMFNkTzdwaGFiUDc0TUJFUGFsY3Bnb0VJZ2V1cExsZXVhQnFnQUJLYTAyWEJNa194VnVLWEV0dDRuemJGWEJ2MEktVWhhUzJfdkRtcVdnakZ0dnl0Rm1pT25tVFJzN0ZfekNrN3pEVGN3UmVGVEp3dVVXZF9IRWVKbk9RMEJZMDNMZlpYbm1RcngwMnRB?oc=5", "source_name": "Investing.com", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Compass Pathways stock rating on FDA progress By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPVDVsbDRncmRUMHlNSjRtU2dNVVJ1X0ZlNWM5X0JYV21veGFYMW1kQVhFWkJOTjJrWFBVeUNaZUVGcE9tV0tNcEJJbTJOLWFDQ20tZFBDTk1vaUljcHNlOUlIcWhxVkR6cXFsakFKR041WXQ0UGoxTm5HSzQ0Y3k1azN0ZWZ2X0kyc3I1OHhQVW9oRHhmRkhocmNPcExMYjU0X1ZPaGRla0p0VVNvcll0VWFfVmpXWHI0cFo2cTFNWEI5WEJlSUNyWmQ0NA?oc=5", "source_name": "Investing.com India", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Compass Pathways stock surging today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNLV85ZGdhNFRna3ROaFVZSHU2NlBiYTdYOGxmUHc4N1Y1eG9CcVpMaGlhdzZTQmduaW5iMDVkTER6QnNoVWpYZXM3bWFtUjF2ZnlfZkczYmNGQ29NZ2VjdkpzWEowa1hhWThBT2hlaG84Q21NZmxncUszYVk0SEJNWkZTbkdBT1NLV3l2UVo2MU9hZm9hcEl3LUczeThBTzgzbG5LUmFYVlo?oc=5", "source_name": "Investing.com", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways stock maintained at Buy by TD Cowen on NDA progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPam5GUUFITUNyMW50MElqS1Y4UEdJdVpJV0lGakJxT3lsTVVnS3BMUUtLb0FIZVlrajFSUWtWdEJLU0JaMExOYklhUExfbHpyN0c5OXZpMlhDalJhVjk5VlpaXzVwamJYNVZfS2ZrTEprSWdvRnh0NWFPTlFmUGtVcWplazhFUEhvWXlfNnJERDVQd095d0Y0OWN4VG5pZDF3cll2anFkeFdEYnd4aVpMclAxMEhhSGNoWFBnbmdMS0s1SUZtbmFn?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Compass Pathways stock rallying today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQeUtCOWlaNkdxSDB5aUtuSTZ0dEowMExIWnZZc2VuUE81T1Q3em9kUHdsZnJaWVV0aDJ1Z0tTU1VWdWU5MlpRYkZFLUJXLWFYWm16b0JTb3dHTUtXUlJlLU1zaWRGNVg0WWV6WGM4alNRSGhhYUVNNThqNElVZ19admlveVhyRFFSOVJHc3lFNk9HOXV2MmtDMFdMTE5DV2h1R3R2ZlNrQ2pBZw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "B.Riley initiates Compass Pathways stock with buy rating, $17 target", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQNTBuVVQ2SV9DWjE5dFlMeC1jLUk1WXlfVTdpMU9SMUdxR1BoLURJbnl0bjBPSVFCdjdXRF9HMmN4b0wyX2pBajRJMHFuZ0xqN29zRlpBcjZ2R3JHWVNnTWlsVWY1d09RaEZETElWZ2h5U0tRVXF3cVBUbnlQb091RVNXRkJWazg2QVZSaFItU3llNlAxaHUyQ25NeWo5TFpyNlhCVkpESjlWdnpYSGRrZlZ2SmlyRXJvb3lkcFgtazZydnM?oc=5", "source_name": "Investing.com", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer reiterates Compass Pathways stock rating on FDA review", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQb0FZZGZwZy01YWhCZjhNNU5tMk9HMm14VzlVU3YyeUhoeXdtVnRqbXdxblFLX3B4UHFXaEhFQ0lSd3l3dFN5MWRzck5aOFFuZlcwTV9HUm1JXzZrQjl3UDZMNl9WVnVOTWtBazVzal8yVG1JYjNVNmVvdE1odHRDYjNSVTc0OWJ0NXRpY2hiUmxPdm1LbUt3bjUwWE9Wc1hIQ2dlUGpfUjJlYzl0UU9PV09TQmRoTFRCVzNuMW42N1IzN1Qy?oc=5", "source_name": "Investing.com", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trump Sends Compass Pathways Stock Soaring as He Backs Psychedelics. Should You Buy CMPS Here?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOckptNXA0TGpTZU5OajR1TkkwSXczaUx0MXlFSS1zeUNSTmFTRDFkSFQtamJkNHZoQWx2VXJudndsQVpUTkIxbWpnS256QzM5ZEp1d3o0V2NiYTNwWEVWOVB0NHFxTGs5VjdtUVBNbUJWN0drQ0RyNk5RckRERzZVUHJsRE1tZlRZY1ZqQjhfR2FmR0dlaXYzV2Q5QVJzb3prLVI4RjRibTduaEtfckJRQVpCU0RIbFVZdnVFOE5GMGR2aEtRX1N1bkRBQTBpeDZmZkE?oc=5", "source_name": "Barchart.com", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley cuts Compass Pathways stock price target on TRD progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPNUlnZXRMclhuMTJBc3MwbjFsSmJhQ3N1SXhuX1BGSC1pYzB2UGV1MC1NNFowbS1YbWt4emJRcXMzU1ZpWkNoN0dEUjN4OWZ2MnBKR215WXgyWFg0MlNkZVduVVpmODhJLUYzWWdLMzhQdWZydWJ3bklKVmpxNFREMWxMSTg0bmU4Z0RYa09FU1FFZGFZU2lob1RycXRqRVNoQ19Ec3lmOXpCemhyMzljWHRWTlJON2Q1NlJxX3JKNzlYcG5mOVUwbVB2Yw?oc=5", "source_name": "Investing.com", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways stock price target raised to $22 by RBC Capital", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOYmNUd1FWaDQ2R3RaMTBtejZuUXVMX2VEcndsNjdZV3VlMkIxTG5jeU5vSlhBaWE1VmV2ZVJBNS1FVXl6TWVJV2t2VU9QQl9fRnNKbGJ0R09MYWpXd3prbzlEQlVuSmNvaHJUVW1mb1pObVI1RU1mbVhzRFNidGNILWxwTmFVb0ZMLUVuOTZueFZZSGFFQl9OWTNQWXVQRUVjbXVHYVlkWG1ycWluQW1rbVRPVW83V2ZUYzZNMWo4R1Q?oc=5", "source_name": "Investing.com", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass stock heads north on psychedelic\u2019s Phase III TRD success", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQWU0yWkFlWEJlWnBIUGw3RmFzUnRnV2haRkY0SWFGakdVdnQ4WVNSYnBQOFItOUQ2N3pxbFkwMTZzbjhqNHpLY2JOOWp4QVNXWjN4TEY4c25zakRNLXhVMHk0QzVvd29NNXdiSUh4QjJGZmgzcnFDd0R6Q0ZJVEFNalpvajJoSHFhSzY3WlNYcHVKNlRadUJZ?oc=5", "source_name": "Clinical Trials Arena", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways stock soars after positive Phase 3 trial results", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPZVdjcjFxSDQ2QUNMS3VPN0E0QjRYTFY4ZFNHelV6OHE2aHRqb0xqUXdLQVZjQVZSbXo1SjFVVkRTS1hEMGdpN3BnS09jamtHRlhBZkRWUFNHOUxUTXpDcXN2dkxKZjhkRmFqaHhCMEk2T2phR2xwalZBRVNxSUE2YzJZcmNOV3E4V1RDWUVyQ2pndDRCWUtZbktCN0w3UmxVTEtmaVBSclEtNDU2STF5Nl9qZWFEZDBZZ2ozQmNBTE5wTWUxMHc?oc=5", "source_name": "Investing.com", "published_at": "2026-02-17T08:00:00+00:00", "published_display": "17 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways stock rating reiterated at Overweight by Cantor Fitzgerald", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOM3N6bUt1VUt2T3k0Ym04bTUxLVRWZU9FOE5JZjZkT1hBSmhmM3NGRmFRbTZnOXZ0NkFpUUM2NFgyQ1JYQzc3NEtMSFlGcmtPNDY4Z04wQ1l3SHIzaEdzZlBydjJSRzlqdTdhZFpwY1VnWU1hMUdndW5NenZkTk5vWTBkbFhibjdqbGM0UEF4SjFiazdkRGpUNHVEUlB1TERza1Y1bDB6WkJvMGtjbDZoYmRKbXM1U2t5TENIZDJhaHZOWmtjQ1V3clAycXljU2Nw?oc=5", "source_name": "Investing.com", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer upgrades Compass Pathways stock to Outperform on FDA pathway", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNa2xZNTRtQ1JXdjB6TE1aeEZOV1U1VzZuV3VhVTNiOWlIRGtONjJ5NnhINEJ6Q0t5RUtoRG5ydXRuS2I5cjlvckhkOG5PVF84dEJ6SHpzNzcwWWRqUDhxSUY0NkNIMHc2dk44cGZYRG1zaGhrdi11QjR3RFNRRHZWbmlmU0dnZm5xNzUwNHhlMF9kV0dCbWM4Szk3VGs5TkN4c0VXWk10clMwNUNNT09IU2JxSWhyZ3c0U3d2OGs5NFJmSThVMU1nNmpqUzk?oc=5", "source_name": "Investing.com", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass\u2019 stock slips despite psilocybin trial hitting target", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQRXFlc2xFcHZEc2k0UHpBa2FNQ21rXzdobzJYMHZKWTFob1Ftd29VR3RuZmN2OV9yM0xFa0NMZjQxY29jTndvMVVIaU45T1JUOFpBdXgzckRNMEZ3ZnR6cmlYcVU2aHVLejFZZGUxLWhmSnFpOF81THhiY2YySDJrSE5PclB2T1lqcGZvbWNmOUVSSVBKRGxpQWRIN2Q1bjVYMldF?oc=5", "source_name": "Clinical Trials Arena", "published_at": "2025-06-24T07:00:00+00:00", "published_display": "24 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Why is Compass Pathways stock being clobbered today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPck03SmxNWGZ6dHh5RGVVcUZKSjA3bFVpdTNsWHlJbFNKR0czdnhIV2UyWm56WTVBdEw1aXc5QWIwWnJBMDVSMkhSOFpGMERhVnJLS3VWQ0FOd1ZBNWpPenVya0ZCQ2F2bUR3QWFJTy1OWjJXSVRtX3hVSHlIbHhyNnFsS1h2T25BeTUzLWt3d3ZHcXRZdEpGdnBUQ2h5NEJ2Z1pNT0VUaTNZa3VLTWVtWHJzbw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways stock rating reaffirmed at Buy by TD Cowen", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPM2VZR2kzNDhxOVRhY2RnbjBSXzlReWx4NG9MSzZNbU1uUHJWd2UxZGFUc1Q2bTgxblRJLWhIYzkzb2JHUHdjNWRZNElBU2ZwOGQydlFwNFVEYkJ5NHpPbWtNS05YUnRHVlZzVVk1d1hQekV2akw2SVYxVVdXbE1JMU90eTVKSHhncU1rYXpYTWFZLXRQd0NVWW5LOGkydHdWODlXUDBJVkwxZ0U4akppN21jUTA5UDNZaHB3?oc=5", "source_name": "Investing.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Compass Pathways stock surging 9% today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQZDFTM09yWXU3QkdLR2dqWXNLc3J0VGhMVVhlNTJDcUZuSXpPdUcwdDJIQWdqNFctTWJPSmx3RFFQTnZMNVh3dS1LS1VXNl8xOXJPQndZUnpON1Mwb205QUROZkoyNjVueHZlMEFSTUY4MEY3d3dWaU1uUzN4b1NicUVXSTZTRGxMLUJrZ1BWai14QjZoQ19TSG9IbVlRWGtTQmtuMlZNU01MUVU?oc=5", "source_name": "Investing.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways stock hits 52-week high at 12.48 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNdGF3dXQ3YVNVYlRWNFBGWTI4TDJFM0FGWWh5OGVBS1o1b1hpTnQ2ckEyaEczbjhlbm5hVU5XWHJjRy1jY0RwbEJ5QXdrNXVtWWwxYnl6cmlUcmxVR2pBdDR3R0htV1VCVG1QSklNazZQLXFVelFqRHU4WHJrTWF1dHpocFF4QURzcm5jUXcyWU9Lamp0RW1fbFVINjNrc212RzRjWVVXd3p1dzNZ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wolfe Research initiates Compass Pathways stock with outperform rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNRGhmTV9WNDRBbEVOdmE0MmM1SDBzNzNlOEl5V01pRDRmaC1oVkdreElSWDhUdm1wSm5pN3JyMFNkTzdwaGFiUDc0TUJFUGFsY3Bnb0VJZ2V1cExsZXVhQnFnQUJLYTAyWEJNa194VnVLWEV0dDRuemJGWEJ2MEktVWhhUzJfdkRtcVdnakZ0dnl0Rm1pT25tVFJzN0ZfekNrN3pEVGN3UmVGVEp3dVVXZF9IRWVKbk9RMEJZMDNMZlpYbm1RcngwMnRB?oc=5", "source_name": "Investing.com", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Compass Pathways stock rating on FDA progress By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPVDVsbDRncmRUMHlNSjRtU2dNVVJ1X0ZlNWM5X0JYV21veGFYMW1kQVhFWkJOTjJrWFBVeUNaZUVGcE9tV0tNcEJJbTJOLWFDQ20tZFBDTk1vaUljcHNlOUlIcWhxVkR6cXFsakFKR041WXQ0UGoxTm5HSzQ0Y3k1azN0ZWZ2X0kyc3I1OHhQVW9oRHhmRkhocmNPcExMYjU0X1ZPaGRla0p0VVNvcll0VWFfVmpXWHI0cFo2cTFNWEI5WEJlSUNyWmQ0NA?oc=5", "source_name": "Investing.com India", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Compass Pathways stock surging today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNLV85ZGdhNFRna3ROaFVZSHU2NlBiYTdYOGxmUHc4N1Y1eG9CcVpMaGlhdzZTQmduaW5iMDVkTER6QnNoVWpYZXM3bWFtUjF2ZnlfZkczYmNGQ29NZ2VjdkpzWEowa1hhWThBT2hlaG84Q21NZmxncUszYVk0SEJNWkZTbkdBT1NLV3l2UVo2MU9hZm9hcEl3LUczeThBTzgzbG5LUmFYVlo?oc=5", "source_name": "Investing.com", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways stock maintained at Buy by TD Cowen on NDA progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPam5GUUFITUNyMW50MElqS1Y4UEdJdVpJV0lGakJxT3lsTVVnS3BMUUtLb0FIZVlrajFSUWtWdEJLU0JaMExOYklhUExfbHpyN0c5OXZpMlhDalJhVjk5VlpaXzVwamJYNVZfS2ZrTEprSWdvRnh0NWFPTlFmUGtVcWplazhFUEhvWXlfNnJERDVQd095d0Y0OWN4VG5pZDF3cll2anFkeFdEYnd4aVpMclAxMEhhSGNoWFBnbmdMS0s1SUZtbmFn?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Compass Pathways stock rallying today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQeUtCOWlaNkdxSDB5aUtuSTZ0dEowMExIWnZZc2VuUE81T1Q3em9kUHdsZnJaWVV0aDJ1Z0tTU1VWdWU5MlpRYkZFLUJXLWFYWm16b0JTb3dHTUtXUlJlLU1zaWRGNVg0WWV6WGM4alNRSGhhYUVNNThqNElVZ19admlveVhyRFFSOVJHc3lFNk9HOXV2MmtDMFdMTE5DV2h1R3R2ZlNrQ2pBZw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "B.Riley initiates Compass Pathways stock with buy rating, $17 target", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQNTBuVVQ2SV9DWjE5dFlMeC1jLUk1WXlfVTdpMU9SMUdxR1BoLURJbnl0bjBPSVFCdjdXRF9HMmN4b0wyX2pBajRJMHFuZ0xqN29zRlpBcjZ2R3JHWVNnTWlsVWY1d09RaEZETElWZ2h5U0tRVXF3cVBUbnlQb091RVNXRkJWazg2QVZSaFItU3llNlAxaHUyQ25NeWo5TFpyNlhCVkpESjlWdnpYSGRrZlZ2SmlyRXJvb3lkcFgtazZydnM?oc=5", "source_name": "Investing.com", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer reiterates Compass Pathways stock rating on FDA review", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQb0FZZGZwZy01YWhCZjhNNU5tMk9HMm14VzlVU3YyeUhoeXdtVnRqbXdxblFLX3B4UHFXaEhFQ0lSd3l3dFN5MWRzck5aOFFuZlcwTV9HUm1JXzZrQjl3UDZMNl9WVnVOTWtBazVzal8yVG1JYjNVNmVvdE1odHRDYjNSVTc0OWJ0NXRpY2hiUmxPdm1LbUt3bjUwWE9Wc1hIQ2dlUGpfUjJlYzl0UU9PV09TQmRoTFRCVzNuMW42N1IzN1Qy?oc=5", "source_name": "Investing.com", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trump Sends Compass Pathways Stock Soaring as He Backs Psychedelics. Should You Buy CMPS Here?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOckptNXA0TGpTZU5OajR1TkkwSXczaUx0MXlFSS1zeUNSTmFTRDFkSFQtamJkNHZoQWx2VXJudndsQVpUTkIxbWpnS256QzM5ZEp1d3o0V2NiYTNwWEVWOVB0NHFxTGs5VjdtUVBNbUJWN0drQ0RyNk5RckRERzZVUHJsRE1tZlRZY1ZqQjhfR2FmR0dlaXYzV2Q5QVJzb3prLVI4RjRibTduaEtfckJRQVpCU0RIbFVZdnVFOE5GMGR2aEtRX1N1bkRBQTBpeDZmZkE?oc=5", "source_name": "Barchart.com", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley cuts Compass Pathways stock price target on TRD progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPNUlnZXRMclhuMTJBc3MwbjFsSmJhQ3N1SXhuX1BGSC1pYzB2UGV1MC1NNFowbS1YbWt4emJRcXMzU1ZpWkNoN0dEUjN4OWZ2MnBKR215WXgyWFg0MlNkZVduVVpmODhJLUYzWWdLMzhQdWZydWJ3bklKVmpxNFREMWxMSTg0bmU4Z0RYa09FU1FFZGFZU2lob1RycXRqRVNoQ19Ec3lmOXpCemhyMzljWHRWTlJON2Q1NlJxX3JKNzlYcG5mOVUwbVB2Yw?oc=5", "source_name": "Investing.com", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways stock price target raised to $22 by RBC Capital", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOYmNUd1FWaDQ2R3RaMTBtejZuUXVMX2VEcndsNjdZV3VlMkIxTG5jeU5vSlhBaWE1VmV2ZVJBNS1FVXl6TWVJV2t2VU9QQl9fRnNKbGJ0R09MYWpXd3prbzlEQlVuSmNvaHJUVW1mb1pObVI1RU1mbVhzRFNidGNILWxwTmFVb0ZMLUVuOTZueFZZSGFFQl9OWTNQWXVQRUVjbXVHYVlkWG1ycWluQW1rbVRPVW83V2ZUYzZNMWo4R1Q?oc=5", "source_name": "Investing.com", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass stock heads north on psychedelic\u2019s Phase III TRD success", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQWU0yWkFlWEJlWnBIUGw3RmFzUnRnV2haRkY0SWFGakdVdnQ4WVNSYnBQOFItOUQ2N3pxbFkwMTZzbjhqNHpLY2JOOWp4QVNXWjN4TEY4c25zakRNLXhVMHk0QzVvd29NNXdiSUh4QjJGZmgzcnFDd0R6Q0ZJVEFNalpvajJoSHFhSzY3WlNYcHVKNlRadUJZ?oc=5", "source_name": "Clinical Trials Arena", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways stock soars after positive Phase 3 trial results", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPZVdjcjFxSDQ2QUNMS3VPN0E0QjRYTFY4ZFNHelV6OHE2aHRqb0xqUXdLQVZjQVZSbXo1SjFVVkRTS1hEMGdpN3BnS09jamtHRlhBZkRWUFNHOUxUTXpDcXN2dkxKZjhkRmFqaHhCMEk2T2phR2xwalZBRVNxSUE2YzJZcmNOV3E4V1RDWUVyQ2pndDRCWUtZbktCN0w3UmxVTEtmaVBSclEtNDU2STF5Nl9qZWFEZDBZZ2ozQmNBTE5wTWUxMHc?oc=5", "source_name": "Investing.com", "published_at": "2026-02-17T08:00:00+00:00", "published_display": "17 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass Pathways stock rating reiterated at Overweight by Cantor Fitzgerald", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOM3N6bUt1VUt2T3k0Ym04bTUxLVRWZU9FOE5JZjZkT1hBSmhmM3NGRmFRbTZnOXZ0NkFpUUM2NFgyQ1JYQzc3NEtMSFlGcmtPNDY4Z04wQ1l3SHIzaEdzZlBydjJSRzlqdTdhZFpwY1VnWU1hMUdndW5NenZkTk5vWTBkbFhibjdqbGM0UEF4SjFiazdkRGpUNHVEUlB1TERza1Y1bDB6WkJvMGtjbDZoYmRKbXM1U2t5TENIZDJhaHZOWmtjQ1V3clAycXljU2Nw?oc=5", "source_name": "Investing.com", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer upgrades Compass Pathways stock to Outperform on FDA pathway", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNa2xZNTRtQ1JXdjB6TE1aeEZOV1U1VzZuV3VhVTNiOWlIRGtONjJ5NnhINEJ6Q0t5RUtoRG5ydXRuS2I5cjlvckhkOG5PVF84dEJ6SHpzNzcwWWRqUDhxSUY0NkNIMHc2dk44cGZYRG1zaGhrdi11QjR3RFNRRHZWbmlmU0dnZm5xNzUwNHhlMF9kV0dCbWM4Szk3VGs5TkN4c0VXWk10clMwNUNNT09IU2JxSWhyZ3c0U3d2OGs5NFJmSThVMU1nNmpqUzk?oc=5", "source_name": "Investing.com", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compass\u2019 stock slips despite psilocybin trial hitting target", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQRXFlc2xFcHZEc2k0UHpBa2FNQ21rXzdobzJYMHZKWTFob1Ftd29VR3RuZmN2OV9yM0xFa0NMZjQxY29jTndvMVVIaU45T1JUOFpBdXgzckRNMEZ3ZnR6cmlYcVU2aHVLejFZZGUxLWhmSnFpOF81THhiY2YySDJrSE5PclB2T1lqcGZvbWNmOUVSSVBKRGxpQWRIN2Q1bjVYMldF?oc=5", "source_name": "Clinical Trials Arena", "published_at": "2025-06-24T07:00:00+00:00", "published_display": "24 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 75, "total_relevant": 19, "sentiment_summary": {"positive": 9, "negative": 1, "neutral": 9, "score": 57, "total": 19, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "analyst", "primary_label": "Analyst action", "confidence": 78, "events": [{"event": "analyst", "label": "Analyst action", "weight": 5.5, "count": 10}, {"event": "general", "label": "Market update", "weight": 4.4, "count": 8}, {"event": "earnings", "label": "Earnings", "weight": 0.55, "count": 1}], "positive_events": 9, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 242.0, "latest_week": "2026-06-12", "one_week_move": 0.0, "four_week_move": 65.8, "twelve_week_move": 120.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.195907, "market_dynamics_buy_signal": false, "relative_strength": 98.482803, "fair_value_gap": 125.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 18.4035, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.0% over one week, +65.8% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 56, "badges": [], "opportunities": [], "risks": [], "event_label": "Analyst action", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Investing.com", "count": 15}, {"label": "Clinical Trials Arena", "count": 2}, {"label": "Investing.com India", "count": 1}, {"label": "Barchart.com", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 19}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Analyst action", "count": 10}, {"label": "Market update", "count": 8}, {"label": "Earnings", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Analyst action", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "19", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+0.0% over one week, +65.8% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Why is Compass Pathways stock being clobbered today?"}], "updated_at": "2026-06-19T16:09:32.539718+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}